Virtual Tumour Proposal

RNS Number : 6814U

Physiomics PLC

04 December 2013

 



Physiomics plc

("Physiomics") or ("the Company")

New Agreement to advance inhibitor of novel target with global pharma company

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a substantial new contract with a major global pharmaceutical company. The programme of studies will begin immediately and take an estimated 9 months to reach a conclusion. Physiomics will determine the optimal dosing regimen of a new compound currently under development by this client. This compound has been shown to block a cellular pathway implicated in cancer growth.  The Company will also determine the optimal chemotherapy combination partner in order to maximise the cancer-killing effects.

The project will be performed on a fee-for-service basis.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to be working with this global pharma on a new target. This is the second such project we have performed for them using the pre-clinical version of Virtual Tumour and further develops a strong relationship based on positive results."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

MSCDMMGZGDKGFZM